Petros Pharmaceuticals In... (PTPI)
| Bid | n/a |
| Market Cap | 14.77M |
| Revenue (ttm) | 5.11M |
| Net Income (ttm) | -20.18M |
| EPS (ttm) | -3.34 |
| PE Ratio (ttm) | -0.08 |
| Forward PE | -0.01 |
| Analyst | n/a |
| Ask | n/a |
| Volume | 16,983,435 |
| Avg. Volume (20D) | 1,668,842 |
| Open | 0.33 |
| Previous Close | 0.01 |
| Day's Range | 0.23 - 0.33 |
| 52-Week Range | 0.23 - 19.16 |
| Beta | 2.09 |
About PTPI
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vac...
2 months ago · accessnewswire.com
Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal StudyProprietary technology utilizing AI and big data integrations to enable Rx to OTC switch candidates across multiple indications NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Petros Pharmaceutic...
2 months ago · accessnewswire.com
Petros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and WarrantsNEW YORK, NY / ACCESS Newswire / February 18, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-t...